Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
As high glucose is able to induce the expression of epidermal growth factor (EGF), which is intimately related with tumor progression, the aim of this study was to evaluate whether curcumin could influence the high glucose-induced EGF/EGFR pathway and the biological activity of pancreatic cancer cells.
|
30542713 |
2019 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We show that CRISPR-mediated knockout of ID1 in glioblastoma cells, breast adenocarcinoma cells, and melanoma cells dramatically reduced tumor progression in all three cancer systems through transcriptional downregulation of EGF, which resulted in decreased EGFR phosphorylation.
|
31292163 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, Epidermal Growth Factor (EGF) promotes tumor progression even with significant EGR1 upregulation.
|
30845713 |
2019 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Together, our findings indicate a complex mechanism underlying PGE<sub>2</sub>-induced EGF/EGFR signaling and transcriptional control, which plays a key role in cancer progression.
|
29599917 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This phenomenon may be attributed to the cross talk between TGF-β signaling and other pathways, including EGF receptor (EGFR) signaling during cancer progression.
|
29215776 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Altogether, our studies reveal a crucial link of EGF receptor to NF-κB activation and tumor progression.
|
27991920 |
2017 |
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Epidermal growth factor receptor (EGFR) and Cortactin are molecular markers that are important in tumour progression and development, and interact within the EGF pathway.
|
29201160 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer.
|
28088463 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results suggest that HB-EGF secreted from KRas-mutated colorectal cancer cells promotes IMF migration through ERK and JNK activation, which, in turn, could support cancer progression.
|
28339087 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
TU-100 and some of its components and metabolites of these components inhibit tumor progression in two mouse models of colon cancer by blocking downstream pathways of EGF receptor activation.
|
27730672 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Therefore, our findings suggest that AQP3 is required for EGF-EGFR cell signaling in cancer cells and is a therapeutic target for cancer progression.
|
26896765 |
2016 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Supporting biological relevance, increased levels of EGF receptor during tumor progression were correlated with increased expression of the UPR gene signature.
|
26551735 |
2016 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Growth factors of the epidermal growth factor (EGF)/neuregulin family are involved in tumor progression and, accordingly, antibodies that intercept a cognate receptor, epidermal growth factor receptor (EGFR)/ERBB1, or a co-receptor, HER2, have been approved for cancer therapy.
|
25915843 |
2016 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Although EGFRvIII is constitutively active and promotes cancer progression, its activity is attenuated compared with EGF-ligated wild-type EGFR, suggesting that EGFRvIII may function together with other signaling receptors in cancer cells to induce an aggressive phenotype.
|
25347738 |
2015 |
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Cripto, the founding member of the EGF-CFC genes, plays an essential role in embryo development and is involved in cancer progression.
|
25629528 |
2015 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Synergistic effect of lung tumor-associated dendritic cell-derived HB-EGF and CXCL5 on cancer progression.
|
24346967 |
2014 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
However, there are limited data regarding the EGF-mediated signaling affecting functional cell properties and the expression of extracellular matrix macromolecules implicated in cancer progression.
|
24792576 |
2014 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The results suggest that proHB-EGF may play an important role in tumor progression.
|
23349913 |
2013 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Epidermal growth factor (EGF) plays a critical role in malignant transformation of hepatocytes and tumor progression.
|
23419149 |
2013 |
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Due to the interaction between HER2 and other ErbB receptors, HER2 is implicated in the EGF family of ligands-regulated tumor progression.
|
23542467 |
2013 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
EGF receptor (EGFR) and MET (the receptor tyrosine kinase for hepatocyte growth factors) are cell-surface tyrosine kinase receptors that have been implicated in diverse cellular processes and as regulators of several microRNAs (miRNAs), thus contributing to tumor progression.
|
23650389 |
2013 |
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
MET, a receptor tyrosine kinase for hepatocyte growth factor, is associated with tumor progression and acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKI).
|
21733594 |
2012 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Although HB-EGF is widely expressed in tumors when compared with normal tissue, its contribution to cancer progression remains obscure.
|
22209887 |
2012 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results indicate that EGF may affect claudins and tight junctional functions in ovarian cancer cells during cancer progression.
|
22544349 |
2012 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
While elevated expression of HB-EGF in cancer cells and its contribution to tumor progression are well documented, the effects of HB-EGF expression in the tumor stroma have not been clarified.
|
22009535 |
2011 |